These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 8497860)

  • 1. alpha-Thrombin within fibrin clots: inactivation of thrombin by antithrombin-III.
    Naski MC; Shafer JA
    Thromb Res; 1993 Mar; 69(5):453-65. PubMed ID: 8497860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A kinetic model for the alpha-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III.
    Naski MC; Shafer JA
    J Biol Chem; 1991 Jul; 266(20):13003-10. PubMed ID: 2071587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The procoagulant effect of zinc on fibrin clot formation.
    Marx G; Eldor A
    Am J Hematol; 1985 Jun; 19(2):151-9. PubMed ID: 4003387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.
    Gandossi E; Lunven C; Berry CN
    Br J Pharmacol; 2000 Mar; 129(5):1021-7. PubMed ID: 10696104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
    Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
    Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin III: a backward glance o'er travel'd roads.
    Seegers WH
    Adv Exp Med Biol; 1975; 52():195-215. PubMed ID: 47704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
    Weitz JI; Leslie B; Hudoba M
    Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.
    von dem Borne PA; Meijers JC; Bouma BN
    Blood; 1995 Oct; 86(8):3035-42. PubMed ID: 7579397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for thrombin enhancement of fibrin polymerization that is independent of its catalytic activity.
    Kaminski M; Siebenlist KR; Mosesson MW
    J Lab Clin Med; 1991 Mar; 117(3):218-25. PubMed ID: 2002278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
    Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
    Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
    Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
    PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
    Hogg PJ; Jackson CM
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3619-23. PubMed ID: 2726739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure of fibrinogen and thrombin to nitric oxide donor ProliNONOate affects fibrin clot properties.
    Helms CC; Kapadia S; Gilmore AC; Lu Z; Basu S; Kim-Shapiro DB
    Blood Coagul Fibrinolysis; 2017 Jul; 28(5):356-364. PubMed ID: 27755019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates.
    Haynes LM; Orfeo T; Mann KG; Everse SJ; Brummel-Ziedins KE
    Biophys J; 2017 Apr; 112(8):1634-1644. PubMed ID: 28445754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin generation and fibrin clot structure.
    Wolberg AS
    Blood Rev; 2007 May; 21(3):131-42. PubMed ID: 17208341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
    Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
    Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.